Sequence: CRGDKGPDC
| Experiment Id | EXP001786 |
|---|---|
| Paper | Cationic microRNA-delivering nanovectors with bifunctional peptides for efficient treatment of PANC- |
| Peptide | CC9 |
| Delivery Success Class | yes |
| In Vivo Flag | yes |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | |
| Endosomal Escape Evidence | |
| Peptide Concentration | Peptide conjugated on polymer (PC-CC9-10% feed); no free peptide added |
| Rna Concentration | miR-34a 15 µM in injection solution; 20 µg per dose (100 µL) |
| Mixing Ratio | N/P = 30 |
| Formulation Format | PC-CC9/miRNA polyplex (covalent peptide-conjugated polymer) for systemic tumor therapy |
| Formulation Components | PC-CC9 (PC-CC9-10% feed) complexed with miR-34a at N/P 30; administered IV to PANC-1 xenograft mice (treatment twice weekly for 2 weeks) |
| Size Nm | 225.00 |
| Zeta Mv | 8.60 |
| Model Scope | in_vivo |
| Model Type | in vivo |
| Cell Lines Or Primary Cells | |
| Animal Model | BALB/c athymic female mice bearing subcutaneous PANC-1 xenografts |
| Administration Route | Intravenous injection (100 µL); twice per week for 2 weeks; dose miR-34a 20 µg per injection |
| Output Type | In vivo antitumor efficacy and tumor apoptosis |
| Output Value | Tumor growth strongly inhibited (tumor volumes <100 mm3 in treated groups); increased TUNEL-positive cells; miR-34a upregulated in tumor; Bcl-2/cyclin D1 reduced |
| Output Units | |
| Output Notes | Tumor targeting supported by increased tumor localization/fluorescence in tumor sections vs non-targeting PC; PET imaging shows reduced tumor signal/size. |
| Toxicity Notes | No major systemic toxicity described in the paper (no detailed body-weight/toxicology focus). |
| Curation Notes |